{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-050951","form_type":"8-K","ticker":"CERO","cik":"0001870404","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2026-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.194092+00:00","generated_at":"2026-05-15T00:22:24.439782+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"CERo Therapeutics issues $500K convertible note to Keystone Capital at 10% interest","bullets":["Initial purchase price $400,000; principal face value $500,000; up to $1M aggregate available.","Note matures April 27, 2027; bears 10% annual interest; convertible at lower of $0.05 or 80% of 5 lowest intraday prices in prior 20 days.","Conversion subject to 4.99% beneficial ownership limitation; resale registration required on Form S-1 or S-3.","Issuance exempt under Section 4(a)(2) and Rule 506(b); accredited investor only."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-050951","json":"https://secwatch.observer/filing/0001213900-26-050951.json","markdown":"https://secwatch.observer/filing/0001213900-26-050951.md","text":"https://secwatch.observer/filing/0001213900-26-050951.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1870404/000121390026050951/0001213900-26-050951-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1870404/000121390026050951/ea028870101-8k_cero.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T00:22:24.439782+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d09c3ea07a974940e7233133a9b69c1e1ce50f4f","claim":"CERO THERAPEUTICS HOLDINGS, INC. incurred convertible notes of $400,000, having a principal face value of $500,000 with Keystone Capital Partners, LLC at 10% per annum maturing April 27, 2027.","evidence_excerpt":"On April 27, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the \"Company\") issued and sold a convertible promissory note for an purchase price of $400,000, having a principal face value of $500,000 (the \"Note\") to Keystone Capital Partners, LLC (\"Lender\").","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390026050951/0001213900-26-050951-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$400,000, having a principal face value of $500,000"},{"label":"Counterparty","value":"Keystone Capital Partners, LLC"},{"label":"Rate","value":"10% per annum"},{"label":"Maturity","value":"April 27, 2027"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"a2143d41a0ccf36e2ea71d93611d4f1842a2cfe7","claim":"CERO THERAPEUTICS HOLDINGS, INC. issued convertible note to Keystone Capital Partners, LLC for $400,000.","evidence_excerpt":"On April 27, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for an purchase price of $400,000, having a principal face value of $500,000 (the “Note”) to Keystone Capital Partners, LLC (“Lender”).","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390026050951/0001213900-26-050951-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"convertible note"},{"label":"Purchaser","value":"Keystone Capital Partners, LLC"},{"label":"Consideration","value":"$400,000"}],"fact_type":"equity_issuance"},{"claim_id":"c96ab91b8a36a1ee3a5ba2adc2ccc7e3a30078b0","claim":"CERO THERAPEUTICS HOLDINGS, INC. entered into Note with Keystone Capital Partners, LLC valued at $400,000 (effective 2026-04-27).","evidence_excerpt":"On April 27, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for an purchase price of $400,000, having a principal face value of $500,000 (the “Note”) to Keystone Capital Partners, LLC (“Lender”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390026050951/0001213900-26-050951-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"notes offering"},{"label":"Counterparty","value":"Keystone Capital Partners, LLC"},{"label":"Value","value":"$400,000"},{"label":"Effective","value":"2026-04-27"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}